How much does a box of ensifentrine-Ohtuvayre cost? Analysis of price fluctuations and purchasing channels

Ensifentrine (Ensifentrine), trade name "Ohtuvayre", is a new inhaled drug mainly used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The drug was developed by the American company Verona Pharma and was approved for marketing by the U.S. FDA in June 2024. In mainland China, Nuance Pharma has obtained the rights to develop and commercialize the drug and plans to submit a new drug application in 2025.

Currently, Ohtuvayre has not been launched in mainland China, nor has it been included in medical insurance. According to information from Hong Kong pharmacies, Ohtuvayre 3mg/2.5mL (60 doses) is priced at 44,500 Hong Kong dollars, which is approximately 5,720 US dollars. Since the drug is not yet available in mainland China, patients who need to use it may need to obtain it through overseas drug purchase channels.

It should be noted that Ohtuvayre has not been approved for sale by the drug administration department in Hong Kong, so there may be risks in terms of legality and quality assurance in the Hong Kong market. When patients consider obtaining the drug through overseas drug purchase channels, they should fully understand the relevant laws and regulations and choose reputable channels to ensure the safety and effectiveness of the drug.

In general, Ohtuvayre, as a new type of COPD treatment, has potential clinical value. However, since it has not yet been marketed in mainland China, patients should be cautious when using it and under the guidance of a professional doctor. As clinical studies advance and regulatory approval is completed, the drug is expected to provide new treatment options for COPD patients in the future.

Reference link:https://www.drugs.com